The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.

Methods and compositions for treating mTBI, PTSD or mTBI with PTSD with psychedelic agents and N-acetylcysteine are provided. Nasal mist transducers for administration of one or more pharmaceutically active ingredients such as these as fine mist particles at preselected dosages and times are also provided.

Methods and compositions for treating mTBI, PTSD or mTBI with PTSD with psychedelic agents and N-acetylcysteine are provided. Nasal mist transducers for administration of one or more pharmaceutically active ingredients such as these as fine mist particles at preselected dosages and times are also provided.

The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquilizers, stimulants and narcotics.

Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.

Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

The invention relates to 3α-ethynyl, 3β-hydroxy, 5α-pregnan-20-oxime or a pharmaceutically acceptable salt thereof, which compounds and/or salts are useful as modulators of the mammal brain excitability via the gamma-5 aminobutyric acid receptor-chloride ionophore (GABA.sub.A-R) complex and in the treatment of disorders such as hepatic encephalopathy, Down's syndrome and Alzheimer's disease.

This invention provides a composition of matter comprising a plurality of cocaine-succinyl-BSA, wherein the average ratio of cocaine-succinyl moieties to BSA is at least 7.0. This invention also provides a composition of matter comprising a plurality of nicotine-5-succinyl-BSA, wherein the average ratio of nicotine-5-succinyl moieties to BSA is at least 7.0. This invention further provides a composition of matter comprising a plurality of methamphetamine-5-succinyl-BSA, wherein the average ratio of methamphetamine-5-succinyl moieties to BSA is at least 7.0. This invention still further provides related pharmaceutical compositions, therapeutic methods, prophylactic methods, synthetic methods, and articles of manufacture.